The oral antiviral drugs for chronic hepatitis B (CHB) on the market can only inhibit the replication of hepatitis B virus. Our Anti-Siglec-3 (CD33) antibody can reactivate CHB patients' immunity to produce anti-HBsAg mAb to clear HBsAg and cure CHB. Also, our novel anti-CD33 mAbs are able to activate brain microglia to uptake beta-amyloid and hyperphosphorylated Tau peptides, which can be seen as a powerful application to improve the clinical outcomes of Alzheimer's disease in the future.